Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 103 of 104, showing 5 Applications out of 518 total, starting on record 511, ending on 515

# Protocol No Study Title Investigator(s) & Site(s)

511.

ECCT/25/03/01   MK-5684_MSD (mCRPC)
     A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA)    
Principal Investigator(s)
1. PROF MANSOOR NOORALI SALEH
Site(s) in Kenya
AGA KHAN UNIVERSITY HOSPITAL NAIROBI
 
View

512.

ECCT/25/03/04   Ndovu RCT
    Investigating the optimal management of dolutegravir resistance: an open-label randomised controlled trial of maintaining dolutegravir or switch to ritonavir-boosted darunavir   
Principal Investigator(s)
1. Loice Achieng Ombajo
Site(s) in Kenya
1. Kenyatta National Hospital (KNH) (Nairobi City county)
2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
3. Bomu Hospital (Mombasa county)
 
View

513.

ECCT/25/03/07   Sparkle - Site 1405
    A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises   
Principal Investigator(s)
1. Prof Videlis Nduba
Site(s) in Kenya
1. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county)
2. Ahero Clinical trials Unit (Kisumu county)
3. International Cancer institute (Uasin Gishu county)
4. Kondele Childrens Hospital (Kisumu county)
5. Gertrudes Children’s Hospital (Nairobi City county)
6. Victoria Biomedical Research Institute (Kisumu county)
 
View

514.

ECCT/25/04/01   PHASE 2/3 OF SII-TCV(B)
    A PHASE 2/3, DOUBLE-BLIND, RANDOMIZED, ACTIVE CONTROLLED STUDY TO EVALUATE THE SAFETY, IMMUNOGENICITY AND IMMUNE NON-INTERFERENCE OF A BIVALENT CONJUGATE VACCINE AGAINST SALMONELLA ENTERICA SEROVARS TYPHI AND PARATYPHI A IN HEALTHY INFANTS AGED 9 TO 12 MONTHS   
Principal Investigator(s)
1. WALTER OTIENO
Site(s) in Kenya
VICTORIA BIOMEDICAL RESEARCH INSTITUTE
 
View

515.

ECCT/25/04/07   Server migration
    Server Migration   
Principal Investigator(s)
1. Server Migration Server Migration
Site(s) in Kenya
Server Migration
 
View